Health Headlines: Lancet Rejects Inquiry, CBD Law Updates, and Device Coverage Accelerations
The Lancet medical journal will not provide evidence for a U.S. Senate COVID-19 inquiry. President Trump urges Congress to update laws for CBD product access. U.S. health regulators plan to expedite Medicare device coverage. The UK investigates data sales on Alibaba. Edwards Lifesciences and Sanofi report earnings, and the FDA fast-tracks psychedelic drug approvals.
The esteemed Lancet medical journal has declined a U.S. Senate request for evidence regarding the COVID-19 origins investigation, according to editor-in-chief Richard Horton. Horton confirmed their decision at a Reuters Pharma event, saying the journal will not participate in the inquiry.
In a recent Truth Social post, President Donald Trump requested Congress to revise current laws to ensure full-spectrum cannabidiol (CBD) product accessibility for Americans. This move reflects ongoing efforts to improve legislative support for CBD usage.
Meanwhile, U.S. health regulators unveiled a new initiative to accelerate Medicare coverage for medical devices. This strategy aims to reduce the reimbursement wait times drastically, encouraging innovation within the medical device industry, which has long faced hurdles due to prolonged approval processes.
(With inputs from agencies.)
- READ MORE ON:
- health
- COVID-19
- Lancet
- Senate
- CBD
- Trump
- Medicare
- medical devices
- FDA
- psychedelic drugs
ALSO READ
GOP Shifts Strategy as Trump's Approval Falls Amid Iran Conflict
Current Health Headlines: Lancet Declines Senate Inquiry, Trump's Drug Pricing Moves, and COVID-19 Vaccine Patent Battle
Trump's Stern Stance: Economic Sanctions Tighten on Iran and China
Iran Prepares Offer to Satisfy U.S. Demands: Trump
Diplomacy in Focus: Trump's Strategic Talks with King Charles
Google News